Compare AbCellera Biologics Inc (ABCL) vs e l f Beauty Inc (ELF) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

ELF Beauty trades at $73.49, down 3.83% recently, but maintains a bullish technical outlook with strong support at $72. The company reported impressive earnings beats in recent quarters with Q4 2025 EPS of $1.24 beating expectations of $0.73. Revenue growth remains robust at $1.31 billion in 2025, though net margins are thin at 1.61%. Analyst sentiment is mixed with 46% buy ratings and a consensus price target of $72.82, slightly below current levels.

The stock faces valuation concerns with a high P/E of 173.68, but strong revenue growth and expansion into haircare and skincare categories provide upside potential. Key risks include tariff exposure and core brand momentum challenges. Institutional ownership trends and recent insider activity suggest cautious optimism as the company executes its diversification strategy.